Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 11/20 | 0.54 |
| ▸ | FAAH | O00519 | 7/20 | 0.54 |
| ▸ | CNR1 | P21554 | 4/20 | 0.54 |
| ▸ | CASR | P41180 | 5/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13766732 | 0.86 | EPHX2 (0.42) | CNR2CNR1EPHX2HTT | |
| SCHEMBL13766918 | 0.84 | CNR2 (0.63) | CNR2FAAHCNR1CASREPHX2 | |
| SCHEMBL13766775 | 0.82 | POLB (0.44) | CNR2FAAHCNR1CASREPHX2 | |
| SCHEMBL17226648 | 0.79 | CNR2 (0.31) | CNR2FAAHCNR1CASRALDH1A1 | |
| SCHEMBL2017354 | 0.77 | CNR2 (0.53) | CNR2FAAHCNR1CASREPHX2 | |
| SCHEMBL14098469 | 0.76 | MERTK (0.37) | CNR2CNR1ALDH1A1 | |
| SCHEMBL17226610 | 0.75 | MEN1 (0.38) | CNR2CNR1ALDH1A1 | |
| SCHEMBL8111487 | 0.75 | CNR2 (0.55) | CNR2FAAHCNR1CASRMAPT | |
| SCHEMBL14098589 | 0.74 | CNR2 (0.50) | CNR2FAAHCNR1CASREPHX2 | |
| SCHEMBL8122848 | 0.74 | CNR2 (0.52) | CNR2FAAHCNR1EPHX2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1953145-B1 | HETEROCYCLIC COMPOUND HAVING INHIBITORY ACTIVITY ON 11-B-HYDROXYSTEROID DEHYDROGENASE TYPE I | SHIONOGI & CO (JP) | 2015-11-04 | — | — | EP | disclosed |
| US-8324265-B2 | Heterocyclic compounds having type I 11β hydroxysteroid dehydrogenase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2012-12-04 | — | — | US | disclosed |
| US-20090170832-A1 | HETEROCYCLIC COMPOUNDS HAVING TYPE I 11beta HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170832-A1 | HETEROCYCLIC COMPOUNDS HAVING TYPE I 11beta HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY | HSD17B1, HSD11B1, HSD3B1 | CNR2 1522/4885FAAH 1693/4885CNR1 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.